Baird upgraded WM (WM) to Outperform from Neutral with a price target of $242, up from $238. The stock’s risk/reward is “compelling” following the year-to-date underperformance, the analyst tells investors in a research note. The firm says WM’s 2026 outlook “looks healthy despite some headwinds.” Baird has confidence that the company’s healthcare solutions issues will be fixed by mid-2026. It sees the stock’s recent selloff as overdone.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WM:
